Australia markets closed

Anavex Life Sciences Corp. (AVXL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.28+0.14 (+2.72%)
At close: 04:00PM EST
5.36 +0.08 (+1.52%)
After hours: 08:00PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 432.73M
Enterprise value 288.97M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.19
Enterprise value/revenue N/A
Enterprise value/EBITDA -6.80

Trading information

Stock price history

Beta (5Y monthly) 0.64
52-week change 3-46.50%
S&P500 52-week change 326.89%
52-week high 310.45
52-week low 34.80
50-day moving average 36.44
200-day moving average 37.33

Share statistics

Avg vol (3-month) 31.46M
Avg vol (10-day) 31.27M
Shares outstanding 582.11M
Implied shares outstanding 682.11M
Float 879.52M
% held by insiders 13.14%
% held by institutions 132.04%
Shares short (15 Feb 2024) 419.89M
Short ratio (15 Feb 2024) 418.41
Short % of float (15 Feb 2024) 425.02%
Short % of shares outstanding (15 Feb 2024) 424.22%
Shares short (prior month 12 Jan 2024) 420.66M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:4
Last split date 307 Oct 2015

Financial highlights

Fiscal year

Fiscal year ends 30 Sept 2023
Most-recent quarter (mrq)31 Dec 2023


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-20.70%
Return on equity (ttm)-31.88%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
Net income avi to common (ttm)-43.16M
Diluted EPS (ttm)-0.54
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)143.76M
Total cash per share (mrq)1.75
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)11.85
Book value per share (mrq)1.65

Cash flow statement

Operating cash flow (ttm)-29.31M
Levered free cash flow (ttm)-17.68M